A study to investigate safety and anti-tumour activity of a Fibroblast Activation Protein (FAP)-targeting radiotracer (177Lu-FO-004) &amp; Safety and Tolerability of a FAP imaging agent (68Ga-3BP-3940) in patients with advanced cancer.

FO-004 - 3B Pharma

Feb 27, 2026